140
Participants
Start Date
June 30, 2014
Primary Completion Date
May 31, 2018
Study Completion Date
June 30, 2018
Apatorsen (OGX-427)
Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
Gemcitabine
"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
Carboplatin
"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
Royal Cornwall Hospitals NHS Trust, Truro
Medway NHS Foundation Trust, Gillingham
Heart of England NHS Foundation Trust, Birmingham
University Hospitals Bristol NHS Foundation Trust, Bristol
Velindre Cancer Centre, Cardiff
Colchester Hospital University NHs Foundation Trust, Colchester
Betsi Cadwaladr University Health Board, Denbighshire
NHS Tayside, Dundee
Royal Surrey County Hospital NHS Foundation Trust, Guildford
NHS Highland, Inverness
Barts Health NHS Trust, London
University College London Hospitals NHS Foundation Trust, London
Royal Free London NHS Foundation Trust, London
Lewisham and Greenwich NHS Trust, London
The Christie NHS Foundation Trust, Manchester
Nottingham University Hospitals NHS Trust, Nottingham
Royal Berkshire NHS Foundation Trust, Reading
Abertawe Bro Morgannwg University Health Board, Swansea
Weston Area Health NHS Trust, Weston-super-Mare
Yeovil District Hospital NHS Foundation Trust, Yeovil
Collaborators (1)
Achieve Life Sciences
INDUSTRY
Queen Mary University of London
OTHER